[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368059-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368059-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-glp-1-agonist-use-and-cancer-risk-in-type-2-diabetes-a-real-world-data-cohort-study","Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes - A Real-World Data Cohort Study","","Background: Determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis changes subsequent risk of overall and site-specific cancer, and whether effects differ by baseline BMI. Methods: Retrospective cohort using TriNetX electronic health records; adults with T2DM diagnosis (2016–2024) receiving hypoglycemic agents within 3 months before/after diagnosis; 1:1 propensity matching (183,264 per group). Outcomes: malignant neoplasms; Cox models, Kaplan–Meier, BMI-stratified analyses. Results: Early use linked to modestly reduced overall cancer risk and lower risks for digestive, respiratory, and female genital cancers; benefits stronger in BMI≥30, including pancreatic and colorectal cancers. Conclusion: Early GLP-1 RA initiation is associated with a modest overall cancer risk reduction, especially in obesity, suggesting dual metabolic and oncologic value.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-glp-1-agonist-use-and-cancer-risk-in-type-2-diabetes-a-real-world-data-cohort-study/368059/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-glp-1-agonist-use-and-cancer-risk-in-type-2-diabetes-a-real-world-data-cohort-study/368059.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s key objective regarding GLP-1 RA and cancer risk?","Question",{"text":63,"@type":64},"To assess whether starting a GLP-1 receptor agonist within 3 months of a T2DM diagnosis changes the risk of overall and site-specific cancers, and whether the association varies by baseline BMI.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were GLP-1 RA users and non-users selected in the cohort?",{"text":68,"@type":64},"Adults aged 20+ diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis, then 1:1 propensity score matching was applied to form comparable groups.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about cancer risk reduction?",{"text":72,"@type":64},"Early GLP-1 RA use showed a modest but statistically significant reduction in overall cancer risk, with lower risks noted for digestive, respiratory, and female genital cancers; stratification indicated stronger benefits in patients with BMI ≥ 30, particularly for pancreatic and colorectal cancers.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368059,1790671016,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Tech Science Press  \n| Doi:10.32604/or.2025.072875\u003Cbr>ARTICLE | \u003Cbr>|\n| --- | --- |\n| Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes: A Real-World Data Cohort Study\u003Cbr>Cheng-Hsun Chuang1,2,3,\\#, Ping-Kun Tsai3,4,5,6,\\#, Shih-Wen Kao7,8, Yu-Hsun Wang8,9, * and Chao-Bin Yeh1,2,3, *\u003Cbr>1 Institute of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan\u003Cbr>2 Department of Emergency Medicine, School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan 3 Department of Emergency Medicine, Chung Shan Medical University Hospital, Taichung, 402, Taiwan 4 Department of Internal Medicine, Zuoying Armed Forces General Hospital, Kaohsiung, 813, Taiwan\u003Cbr>5 Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, 114, Taiwan 6 Graduate Institute of Aerospace and Undersea Medicine, College of Biomedical Sciences, National Defense Medical University, Taipei,114, Taiwan\u003Cbr>7 Department of Orthopedic Surgery, Chung Shan Medical University Hospital, Taichung, 402, Taiwan 8 School of Medicine, Chung Shan Medical University, Taichung, 402, Taiwan\u003Cbr>9 Department of Medical Research, Chung Shan Medical University Hospital, Taichung, 402, Taiwan\u003Cbr>*[Corresponding Authors: Yu-Hsun Wang. Email: cshe731@csh.org.tw](Corresponding Authors: Yu-Hsun Wang. Email: cshe731@csh.org.tw); [Chao-Bin Yeh. Email: sky5ff@gmail.com](Chao-Bin Yeh. Email: sky5ff@gmail.com)\u003Cbr>\\# These authors contributed equally to this work\u003Cbr>Received: 05 September 2025; Accepted: 29 October 2025; Published: 30 December 2025\u003Cbr>ABSTRACT: Background: To determine whether initiating a glucagon-like peptide-1 receptor agonist (GLP-1 RA) within 3 months of type 2 diabetes (T2DM) diagnosis alters the subsequent risk of overall and site-specific cancer and whether this association differs by baseline body-mass index (BMI) . Methods: This retrospective cohort study used electronic health records from the TriNetX U.S. research network. Adults aged 20 years or older diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis. Following 1:1 propensity score matching, both the GLP-1 RA user and non-user groups included 183,264 patients. The study outcome was defined as a diagnosis of malignant neoplasms. Hazard ratios (HRs) for overall and site-specific cancer risk were estimated using Cox proportional hazards models. Kaplan–Meier analysis and stratified analysis by BMI were performed. Results: Early GLP-1 RA use demonstrated a modest but significant association with reduced overall cancer risk (HR 0.93; 95% CI: 0.90–0.96) . Reduced risks were noted for cancers of the digestive (HR 0.81), respiratory (HR 0.66), and female genital (HR 0.87) systems. In stratified analysis, benefits were more pronounced in patients with BMI ≥ 30, particularly for pancreatic and colorectal cancers. Conclusion: Early initiation of GLP-1 receptor agonists in patients with diagnosed T2DM was associated with a modest reduction in overall cancer risk, particularly among individuals with obesity. These findings highlight the dual metabolic and oncologic value of prompt GLP-1 RA therapy.\u003Cbr>KEYWORDS: Glucagon-like peptide-1 (GLP-1) receptor agonists; type 2 diabetes mellitus; cancer risk; obesity; cohort study |  |\n\n1 Introduction  \nGlucagon-like peptide-1 receptor agonist (GLP-1 RA) is a class of incretin-based therapies widely used in the management of type 2 diabetes mellitus (T2DM) . By mimicking endogenous GLP-1, these  \nCopyright © 2026 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nagents enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety [1,2]. GLP-1 effects are mediated through t","cbCaip9suN3uJlrP","https://ap.wps.com/l/cbCaip9suN3uJlrP","pdf",2376521,17,"English","# Introduction\n## Study background and rationale\n## GLP-1 RA mechanisms and clinical uses\n## Safety concerns and prior evidence","[{\"question\":\"What was the study’s key objective regarding GLP-1 RA and cancer risk?\",\"answer\":\"To assess whether starting a GLP-1 receptor agonist within 3 months of a T2DM diagnosis changes the risk of overall and site-specific cancers, and whether the association varies by baseline BMI.\"},{\"question\":\"How were GLP-1 RA users and non-users selected in the cohort?\",\"answer\":\"Adults aged 20+ diagnosed with T2DM between 2016 and 2024 were included if they received any hypoglycemic agents within 3 months before and after diagnosis, then 1:1 propensity score matching was applied to form comparable groups.\"},{\"question\":\"What did the results show about cancer risk reduction?\",\"answer\":\"Early GLP-1 RA use showed a modest but statistically significant reduction in overall cancer risk, with lower risks noted for digestive, respiratory, and female genital cancers; stratification indicated stronger benefits in patients with BMI ≥ 30, particularly for pancreatic and colorectal cancers.\"}]","Early GLP-1 Agonist Use and Cancer Risk in Type 2 Diabetes - A Real-World Data Cohort Study | PDF",1790174726,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d91c1d1fb7a39f435240e1fa005bc839.webp",983,1271,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60cea1eb364ca9b095076512624ed26d.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/99130bcfac1a373a49619ab6aa7958bf.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02c049e90a4b8b636964eef65f59f1cd.webp",980,1267]